(NASDAQ: LIVN) Livanova's forecast annual revenue growth rate of 6.86% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.83%.
Livanova's revenue in 2026 is $1,433,456,000.On average, 13 Wall Street analysts forecast LIVN's revenue for 2026 to be $84,432,847,906, with the lowest LIVN revenue forecast at $80,038,164,866, and the highest LIVN revenue forecast at $87,344,325,420. On average, 13 Wall Street analysts forecast LIVN's revenue for 2027 to be $90,420,603,548, with the lowest LIVN revenue forecast at $85,201,917,438, and the highest LIVN revenue forecast at $95,694,223,196.
In 2028, LIVN is forecast to generate $96,023,824,424 in revenue, with the lowest revenue forecast at $88,717,663,870 and the highest revenue forecast at $106,955,598,486.